Lecture Details - Overview
E-Lert: Emerging Therapies for Advanced Prostate Cancer
Release Date: November 25, 2009|
Expiration Date: November 25, 2010
0.5 AMA PRA Category 1 Credit(s)™|
Nov 25, 2009, E-Lert
Upon completion of this educational activity, you should be able to:
- Evaluate the safety and efficacy of new cytotoxic, endocrine, and targeted therapies for the treatment of patients with CRPC
- Appraise novel bone-targeted therapies for patients with advanced prostate cancer
Interview With: Nancy Dawson, MD, FACP
Overview and Purpose
Treatment options for castration-resistant prostate cancer (CRPC) are limited, with a modest 3-month improvement in median overall survival with docetaxel-based chemotherapy, the current standard of care. At disease progression, there is no accepted salvage therapy. Patients frequently suffer significant and debilitating comorbidities resulting from the propensity of prostate cancer cells to metastasize to bone. Recently, a variety of agents, including epothilones, vaccines, endothelin A receptor antagonists, and androgen synthesis or signaling inhibitors, have shown activity in both first and subsequent lines of therapy for CRPC. A novel RANKL (receptor activator of nuclear factor-κB ligand) inhibitor has demonstrated efficacy in preventing bone complications in patients with prostate cancer. Clinical development of these agents is continuing in ongoing phase III trials.
The purpose of this activity is to update physicians on emerging therapies and ongoing clinical trials for the treatment of patients with advanced CRPC.
This educational activity is intended for medical oncologists involved in the care of patients with prostate cancer. No specific skills or knowledge other than a basic training in oncology is required for successful participation in this activity.
Choose a Participation Option
To claim credit for this activity you must:
- Take the Pretest
- Participate in the Activity
- Take the Posttest
- Take the Evaluation
- Claim your Credit Amount & Certificate Type
If you do not wish to claim credit:
You may bypass all CE information, tests and evaluations and go straight to the activity.
You may not request credit after viewing the activity.
I wish to participate in this
activity and claim credit.
I wish to view the activity
without claiming credit.
